Belvedere Trading
PHAT icon

Belvedere Trading’s Phathom Pharmaceuticals PHAT Stock Holding History

Belvedere Trading’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,525
Closed -$96.6K – 1058
2023
Q1 		$96.6K Buy
+13,525
New +$119K ﹤0.01% 474

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Belvedere Trading's PHAT Position: Q2 2023 in Review

Belvedere Trading sold out of Phathom Pharmaceuticals (PHAT) in Q2 2023, closing a stake of 13,525 shares — an estimated $96.6K sold.

Belvedere Trading first reported a position in PHAT in Q1 2023 and held it in 1 quarter. The position peaked at $96.6K in Q1 2023. 103 funds tracked by Wall St. Rank hold PHAT as of Q2 2023.

  • Belvedere Trading reported no remaining Phathom Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belvedere Trading sold 13,525 Phathom Pharmaceuticals shares in Q2 2023, an estimated $96.6K.
  • Belvedere Trading first reported a position in Phathom Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Belvedere Trading's Phathom Pharmaceuticals position peaked at $96.6K in Q1 2023.
  • 103 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.